Results 171 to 180 of about 128,678 (309)

Uncovering hypertrophic cardiomyopathy pathophysiology – the unsolved role of microvascular dysfunction

Revista Portuguesa de Cardiologia, 2022
Alexandra Toste
doaj   +1 more source

Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction

British Journal of Pharmacology, Volume 183, Issue 5, Page 990-1008, March 2026.
Background and Purpose Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses.
Erik Klapproth, Johanna Marks, Patrick Diaba‐Nuhoho, Sören Grell, Paul Leubauer, Susanne Kämmerer, Johannes R. Soltwedel, Fred Rasmussen, Felix Mejia, Marcia L. Moss, Christopher Prince, Peter Mirtschink, Ben Wielockx, Paul Saftig, Michael Wagner, Kristina Lorenz, Ali El‐Armouche   +16 more
wiley   +1 more source

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Ahmad Masri, Iacopo Olivotto
doaj   +1 more source

Programmed ventricular stimulation for risk stratification in hypertrophic cardiomyopathy patients [PDF]

Πέτρος Αρσένος, Konstantinos Tsioufis, Konstantinos Gatzoulis   +2 more
openalex   +1 more source

Surgical septal myectomy outcome for obstructive hypertrophic cardiomyopathy after alcohol septal ablation [PDF]

, 2021
Qiulan Yang, Changsheng Zhu, Hao Cui, Bing Tang, Shuiyun Wang, Qinjun Yu, Shihua Zhao, Yunhu Song, Shuiyun Wang   +8 more
openalex   +1 more source

Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis

British Journal of Pharmacology, Volume 183, Issue 5, Page 1030-1047, March 2026.
Background and Purpose Myocardial fibrosis (MF), a hallmark of structural cardiac remodelling, drives disease progression across most forms of heart failure and plays a central role in heart failure with preserved ejection fraction (HFpEF). Despite its clinical relevance, effective treatments remain scarce.
Sheyla Barrado‐Ballestero, Sarah Torp Yttergren, Max Hahn, Marie Biviano Rosenkilde, Ditte Marie Jensen, Michael Christensen, Louise Thisted, Heidi Lindgreen Holmberg, Geoffrey Teixeira, Tor Biering‐Sørensen, Casper Gravesen Salinas, Urmas Roostalu   +11 more
wiley   +1 more source

Surgical management of hypertrophic cardiomyopathy. [PDF]

Indian J Thorac Cardiovasc Surg
Ananthanarayanan C, Modugula SR, Chauvette V, Ragheb D, Bhagat R, Smedira N.   +5 more
europepmc   +1 more source

Recurrent repolarisation abnormalities in an athlete. [PDF]

, 2013
A Pelliccia, AP Burke, BJ Maron, D Corrado, IA Rijsingen Van, JA Drezner, JA Drezner, JE Madias, M Papadakis, N Chandra, S Basavarajaiah, S Sharma   +11 more
core   +1 more source

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy

British Journal of Pharmacology, Volume 183, Issue 5, Page 1122-1139, March 2026.
Abstract Background and Purpose Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM). Despite its recent approval for clinical use, the transcriptional and functional impacts of MAVA remain not well understood.
Elisa Kiselev, Wilson Agyapong, Bjarne Jürgens, Elisa Mohr, Shambhabi Chatterjee, Hannah J. Hunkler, Jawad Salman, Giuseppe Cipriano, Marco Bentele, Junqing Liu, Jonas Specht, Kaja S. Menge, Florian J. G. Waleczek, Jonas A. Haas, Anselm A. Derda, Kristina Sonnenschein, Anika Gietz, Susanne Neumüller, Angelika Pfanne, Oliver Beetz, Michael Pflaum, Bettina Wiegmann, Yiangos Psaras, Christopher Toepfer, Robert Zweigerdt, Ante Radocaj, Theresia Kraft, Andre Zeug, Evgeni Ponimaskin, Wilhelm Korte, Alexander Horke, Arjang Ruhparwar, Maximilian Fuchs, Ke Xiao, Christian Bär, Natalie Weber, Thomas Thum   +36 more
wiley   +1 more source

Septal Reduction Therapy for Obstructive Hypertrophic Cardiomyopathy: Volume Still Matters for Septal Myectomy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Vincent Y. See, Libin Wang
doaj   +1 more source